成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Duvelisib (IPI-145)

別名: INK1197 中文名稱(chēng):杜韋利西布

Duvelisib (IPI-145, INK1197) 是一種新型選擇性PI3K δ/γ抑制劑,在無(wú)細(xì)胞試驗(yàn)中KiIC50分別為 23 pM/243 pM 和 1 nM/50 nM,對(duì) PI3K δ/γ 的選擇性比對(duì)其它蛋白激酶高。Phase 3。

Duvelisib (IPI-145) Chemical Structure

Duvelisib (IPI-145) Chemical Structure

CAS: 1201438-56-3

規(guī)格 價(jià)格 庫(kù)存 購(gòu)買(mǎi)數(shù)量
10mM (1mL in DMSO) 1557.22 現(xiàn)貨
5mg 1409.65 現(xiàn)貨
50mg 7967.14 現(xiàn)貨
1g 31900 現(xiàn)貨
更大包裝 有超大折扣

400-668-6834

info@selleck.cn

免費(fèi)分裝
免費(fèi)預(yù)溶

Duvelisib (IPI-145)相關(guān)產(chǎn)品

相關(guān)信號(hào)通路圖

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

細(xì)胞系 實(shí)驗(yàn)類(lèi)型 給藥濃度 孵育時(shí)間 活性描述 文獻(xiàn)信息
BJAB Cell viability assay 0.1, 1, 5 μM 48 and 72 h inhibited cell growth 29522278
LCL Cell viability assay 0.1, 1, 5 μM 48 and 72 h inhibited cell growth 29522278
Ramos460 Function assay 1 μM effectively impaired the phosphorylation of Akt 30584254
Raji32 Function assay 1 μM effectively impaired the phosphorylation of Akt 30584254
MOLT3 Function assay 0.1, 1.0, and 9.0 μM IPI145 was able to inhibit Akt and S6 phosphorylation but barely affected the growth of MOLT3 T-ALL 30970263
JURKAT Function assay 0.1, 1.0, and 9.0 μM IPI145 was able to inhibit Akt and S6 phosphorylation and modestly affected growth in JURKAT 30970263
Loucy Proliferation assay 3 days Antiproliferative activity against human Loucy cells after 3 days by CellTiter-Glo assay, IC50=0.98 μM 27774127
MOLM14 Proliferation assay 3 days Antiproliferative activity against human MOLM14 cells after 3 days by CellTiter-Glo assay, IC50=1.2 μM 27774127
MV4-11 Proliferation assay 3 days Antiproliferative activity against human MV4-11 cells after 3 days by CellTiter-Glo assay, IC50=4.4 μM 27774127
MOLT4 Proliferation assay 3 days Antiproliferative activity against human MOLT4 cells after 3 days by CellTiter-Glo assay, IC50=2.3 μM 27774127
Jurkat Proliferation assay 3 days Antiproliferative activity against human Jurkat cells after 3 days by CellTiter-Glo assay, IC50=1.9 Μm 27774127
insect cells Function assay 5 mins Inhibition of recombinant human C-terminal His6-tagged p110gamma expressed in insect cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin layer chromatographic method, IC50 = 0.1 μM. ChEMBL
Sf21 Function assay 5 mins Inhibition of N-terminal His6-tagged recombinant full-length human p110delta/untagged recombinant full length p85alpha expressed in baculovirus infected Sf21 cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin l, IC50 = 0.1 μM. ChEMBL
splenic B Antiproliferative assay 30 mins Antiproliferative activity against Balb/c mouse splenic B cells preincubated for 30 mins followed by LPS or F(ab')2 donkey anti-mouse IgM and recombinant mouse IL4 stimulation measured after 72 hrs by Alamar Blue reduction assay, EC50 = 0.1 μM. ChEMBL
Sf21 Function assay 5 mins Inhibition of N-terminal His6-tagged recombinant full-length human p110beta/untagged recombinant full length p85alpha expressed in baculovirus infected Sf21 cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by thin la, IC50 = 1 μM. ChEMBL
Sf21 Function assay 5 mins Inhibition of N-terminal His6-tagged recombinant full-length human p110alpha/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 cells using phosphatidylinositol as substrate in presence of gamma-32P-ATP after 5 mins by , IC50 = 10 μM. ChEMBL
OCI-Ly3 Growth inhibition assay GI50=3.7 μM 30067771
HBL-1 Growth inhibition assay GI50=5.3 μM 30067771
TMD-8 Growth inhibition assay GI50=0.0005 μM 30067771
U-2932 Growth inhibition assay GI50=1.8 μM 30067771
Farage Growth inhibition assay GI50=0.04 μM 30067771
SU-DHL-10 Growth inhibition assay GI50=2.4 μM 30067771
SU-DHL-4 Growth inhibition assay GI50=0.2 μM 30067771
Karpas-422 Growth inhibition assay GI50=0.1 μM 30067771
DOHH-2 Growth inhibition assay GI50=0.05 μM 30067771
WSU-NHL Growth inhibition assay GI50=0.008 μM 30067771
Jeko-1 Growth inhibition assay GI50=1.3 μM 30067771
Mino Growth inhibition assay GI50=3.4 μM 30067771
NCI-H929 Growth inhibition assay GI50=1 μM 30067771
HH Growth inhibition assay GI50=0.01 μM 30067771
點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù)

生物活性

產(chǎn)品描述 Duvelisib (IPI-145, INK1197) 是一種新型選擇性PI3K δ/γ抑制劑,在無(wú)細(xì)胞試驗(yàn)中KiIC50分別為 23 pM/243 pM 和 1 nM/50 nM,對(duì) PI3K δ/γ 的選擇性比對(duì)其它蛋白激酶高。Phase 3。
靶點(diǎn)
PI3Kδ [1]
(Cell-free assay)
PI3Kβ [1]
(Cell-free assay)
PI3Kγ [1]
(Cell-free assay)
23 pM(Ki) 1564 pM(Ki) 243 pM(Ki)
體外研究(In Vitro)
體外研究活性

IPI-145抑制鼠/人類(lèi) B細(xì)胞增殖,EC50 為0.5 nM/0.5 nM,也抑制人類(lèi)T細(xì)胞增殖,EC50為9.5 nM。[1]

實(shí)驗(yàn)圖片 檢測(cè)方法 檢測(cè)指標(biāo) 實(shí)驗(yàn)圖片 PMID
Western blot PI3Kγ / PI3Kδ p-AKT / AKT / p-MAPK / MAPK 29522278
體內(nèi)研究(In Vivo)
體內(nèi)研究活性

IPI-145 按10 mg/kg劑量口服處理給藥小鼠和大鼠,具有良好的藥代動(dòng)力學(xué), Cmax 和AUC分別為390 ng/mL 和 137 ng•h/mL。IPI-145 (10 mg/kg) 有效作用于鼠DTH 模型,約~50% 耳腫脹。IPI-145 (10 mg/kg) 有效作用于大鼠膠原誘導(dǎo)的關(guān)節(jié)炎(CIA)模型,這種作用具有劑量依賴(lài)性。IPI-145 作用于大鼠CIA模型,防止發(fā)炎,且保護(hù)關(guān)節(jié)骨和軟骨。IPI-145 (10 mg/kg,QD)有效作用于大鼠佐劑性多關(guān)節(jié)炎模型。[1]

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02307461 Completed
Healthy
SecuraBio
November 2014 Phase 1
NCT02095587 Completed
Hepatic Impairment
SecuraBio
March 2014 Phase 1
NCT01947777 Completed
Healthy
SecuraBio
October 2013 Phase 1
NCT01925911 Completed
Healthy
SecuraBio
August 2013 Phase 1
NCT01836861 Completed
Healthy
SecuraBio
March 2013 Phase 1
NCT01549106 Completed
Healthy Volunteers
SecuraBio
August 2011 Phase 1

化學(xué)信息&溶解度

分子量 416.86 分子式

C22H17ClN6O

CAS號(hào) 1201438-56-3 SDF Download Duvelisib (IPI-145) SDF
Smiles CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
儲(chǔ)存條件(自收到貨起)

體外溶解度
批次:

DMSO : 83 mg/mL ( (199.1 mM) ;DMSO吸濕會(huì)降低化合物溶解度,請(qǐng)使用新開(kāi)封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩爾濃度計(jì)算器

體內(nèi)溶解度
批次:

現(xiàn)配現(xiàn)用,請(qǐng)按從左到右的順序依次添加,澄清后再加入下一溶劑

動(dòng)物體內(nèi)配方計(jì)算器

實(shí)驗(yàn)計(jì)算

摩爾濃度計(jì)算器

質(zhì)量 濃度 體積 分子量

動(dòng)物體內(nèi)配方計(jì)算器(澄清溶液)

第一步:請(qǐng)輸入基本實(shí)驗(yàn)信息(考慮到實(shí)驗(yàn)過(guò)程中的損耗,建議多配一只動(dòng)物的藥量)

mg/kg g μL

第二步:請(qǐng)輸入動(dòng)物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請(qǐng)聯(lián)系Selleck為您提供正確的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計(jì)算結(jié)果:

工作液濃度: mg/ml;

DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,:如該濃度超過(guò)該批次藥物DMSO溶解度,請(qǐng)先聯(lián)系Selleck);

體內(nèi)配方配制方法:μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。

體內(nèi)配方配制方法:μL DMSO母液,加入μL Corn oil,混勻澄清。

注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購(gòu)、運(yùn)輸、儲(chǔ)存和使用我們的產(chǎn)品的任何階段,您遇到的任何問(wèn)題,均可以通過(guò)撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會(huì)在24小時(shí)內(nèi)盡快聯(lián)系您。

操作手冊(cè)

如果有其他問(wèn)題,請(qǐng)給我們留言。

* 必填項(xiàng)

請(qǐng)輸入您的姓名
請(qǐng)輸入您的郵箱地址 請(qǐng)輸入一個(gè)有效的郵箱地址
請(qǐng)寫(xiě)點(diǎn)東西給我們

常見(jiàn)問(wèn)題及建議解決方法

問(wèn)題 1:
Whether IPI-145 S7028 is mixture of two chiral forms, if not, which form is it?

回答:
S7028 IPI-145 is S form.

Tags: buy Duvelisib (IPI-145) | Duvelisib (IPI-145) supplier | purchase Duvelisib (IPI-145) | Duvelisib (IPI-145) cost | Duvelisib (IPI-145) manufacturer | order Duvelisib (IPI-145) | Duvelisib (IPI-145) distributor
在線咨詢(xún)
聯(lián)系我們